Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0588 CHF | +6.91% | +13.95% | +43.41% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.41% | 4.07M | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-22.70% | 29.36B | |
+58.56% | 24.49B | |
-14.15% | 17.31B | |
-18.65% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Polyphor Treats First Patient in Early-Stage Study of Inhaled Antibiotic